

# Ethiopia Support for Inactivated Polio Vaccine (IPV)

# This Decision Letter sets out the Programme Terms of a Programme.

	Country: Ethiopia				
2.	Grant number: 1518-ETH-25c-X				
3.	Date of Decision Letter: 07 April 2017				
4.	Date of the Partnership Framework Agreement: 23 July 2013				
5.	Programme title: NVS, IPV routine				
6.	Vaccine type: Inactivated Polio Vaccine (IPV)				
7.	Requested product presenta 10 dose(s) per vial, LIQUID	tion and formulation	n of vaccine <sup>1</sup> : Ina	activated Polio Va	
8.	Programme duration <sup>2</sup> : 2015-2017				
pro	ocesses.				
	Programme Budget (US\$)	2015-2016 US\$4,269,162	2017 US\$3,556,500	Total <sup>3</sup> US\$7,825,662	
	. Vaccine introduction grant	US\$4,269,162  : Not applicable	US\$3,556,500	US\$7,825,662	
		US\$4,269,162  : Not applicable	US\$3,556,500	US\$7,825,662	
	. Vaccine introduction grant	US\$4,269,162  : Not applicable  s: (subject to the terms	US\$3,556,500	US\$7,825,662	
	Vaccine introduction grant  Indicative Annual Amounts Agreement, if applicable)4	US\$4,269,162  : Not applicable  : (subject to the terms ased with Gavi funds	US\$3,556,500	US\$7,825,662	
	Vaccine introduction grant  Indicative Annual Amounts Agreement, if applicable) <sup>4</sup> Type of supplies to be purch	US\$4,269,162  : Not applicable  : (subject to the terms ased with Gavi funds	US\$3,556,500	US\$7,825,662 nip Framework	
11.	. Vaccine introduction grant  . Indicative Annual Amounts Agreement, if applicable) <sup>4</sup> Type of supplies to be purch  Number of IPV vaccines dos	US\$4,269,162  : Not applicable  s: (subject to the terms ased with Gavi funds es	US\$3,556,500	US\$7,825,662 hip Framework 2017 3,968,000	
11.	. Vaccine introduction grant  Indicative Annual Amounts Agreement, if applicable) <sup>4</sup> Type of supplies to be purch Number of IPV vaccines dos Annual Amounts (US\$)	US\$4,269,162  : Not applicable  s: (subject to the terms ased with Gavi funds es	US\$3,556,500	US\$7,825,662 hip Framework 2017 3,968,000	

<sup>&</sup>lt;sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>&</sup>lt;sup>2</sup> This is the entire duration of the Programme.

<sup>&</sup>lt;sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2017.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.



#### 15. Operational support for campaigns: N/A

# 16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of	May
vaccines, Country shall submit the following	
information in May each year: number of children	
to be vaccinated, vaccine stock levels including	
buffer stock, wastage rates, any proposed	
changes in presentation or minimum co-financing	
levels and vaccines received.	
In accordance with applicable Gavi processes,	To be agreed with Secretariat
Country shall report on programmatic and	
financial performance.	

## 17. Financial clarifications: N/A

### 18. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by, On behalf of Gavi

Hind Khatib-Othman Managing Director, Country Programmes

Lebar . Ho h

07 April 2017